The OKT3 antibody response study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ tranplantation

JA A. Kimball, Douglas Norman, CF F. Shield, TJ J. Schroeder, P. Lisi, M. Garovoy, JB B. O'Connell, F. Stuart, SV V. McDiarmid, W. Wall

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Human anti-murine antibody titres following patient exposure to the monoclonal antibody Orthoclone OKT®3 (muromonab-CD3) are determined by laboratories using diverse analytical methods which are not standardized and whose concordance is not established. A multicentre study group therefore compared testing for IgG anti-OKT3 antibody among seven laboratories. A set of 270 sera was obtained from 30 heart, 30 kidney and 30 liver transplant recipients with no previous exposure to OKT3 who were receiving OKT3 for induction immunosuppression. Sera were collected from each patient prior to and at 24 ± 2 days and 31 ± 2 days following initial OKT3 exposure. Identical aliquots of all 270 sera were tested for IgG anti-OKT3 antibody by each laboratory. In addition, the limit of detection of each laboratory's method was estimated by titration of an affinity-purified IgG anti-OKT3 reference material of known concentration. Anti-OKT3 antibody formation differed greatly among the three organ groups. Cardiac patients demonstrated the least sensitization and almost exclusively lower titres, while kidney recipients had more frequent and higher titre antibody formation. Liver recipients yielded the highest sensitization rate and the most frequent high titre sera. Importantly, the seven laboratories differed widely in the number of pretreatment sera reported as positive (ranging from 0% to 41% among laboratories), the number of post-OKT3 sera reported as positive (17-63%), the number of post-OKT3 samples with titre ≥1000 (2-31%), and the number of agreement ranging from 38% to 83% on the sample titres assigned to 180 post-OKT3 sera. Many of the discordant results were consistent with differences in the limit of detection of the analytical methods, which ranged from 0.19 μg/ml to ≥15 μg/ml, a nearly 100-fold difference among laboratories. This study demonstrated the presence of both good concordance and significant discordance among laboratories in determining human anti-mouse antibody titres, and demonstrated that common titre categories (100, 1000, 10 000) were not equivalent among laboratories. The level of concordance among methods should be considered when comparing anti-OKT3 antibody results from different centres and their correlation with clinical events. Universal comparative testing, patterned after proficiency testing programmes, is needed to assess differences among laboratories and to bring uniformity and a sound interpretative basis to this field of testing.

Original languageEnglish (US)
Pages (from-to)212-221
Number of pages10
JournalTransplant Immunology
Volume3
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Muromonab-CD3
Multicenter Studies
Antibody Formation
Anti-Idiotypic Antibodies
Serum
Limit of Detection
Immunoglobulin G
Kidney
Liver
Immunosuppression

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Transplantation

Cite this

The OKT3 antibody response study : a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ tranplantation. / Kimball, JA A.; Norman, Douglas; Shield, CF F.; Schroeder, TJ J.; Lisi, P.; Garovoy, M.; O'Connell, JB B.; Stuart, F.; McDiarmid, SV V.; Wall, W.

In: Transplant Immunology, Vol. 3, No. 3, 1995, p. 212-221.

Research output: Contribution to journalArticle

Kimball, JAA, Norman, D, Shield, CFF, Schroeder, TJJ, Lisi, P, Garovoy, M, O'Connell, JBB, Stuart, F, McDiarmid, SVV & Wall, W 1995, 'The OKT3 antibody response study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ tranplantation', Transplant Immunology, vol. 3, no. 3, pp. 212-221. https://doi.org/10.1016/0966-3274(95)80027-1
Kimball, JA A. ; Norman, Douglas ; Shield, CF F. ; Schroeder, TJ J. ; Lisi, P. ; Garovoy, M. ; O'Connell, JB B. ; Stuart, F. ; McDiarmid, SV V. ; Wall, W. / The OKT3 antibody response study : a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ tranplantation. In: Transplant Immunology. 1995 ; Vol. 3, No. 3. pp. 212-221.
@article{b01c3b516afb499a9de6fd4e9afc5abc,
title = "The OKT3 antibody response study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ tranplantation",
abstract = "Human anti-murine antibody titres following patient exposure to the monoclonal antibody Orthoclone OKT{\circledR}3 (muromonab-CD3) are determined by laboratories using diverse analytical methods which are not standardized and whose concordance is not established. A multicentre study group therefore compared testing for IgG anti-OKT3 antibody among seven laboratories. A set of 270 sera was obtained from 30 heart, 30 kidney and 30 liver transplant recipients with no previous exposure to OKT3 who were receiving OKT3 for induction immunosuppression. Sera were collected from each patient prior to and at 24 ± 2 days and 31 ± 2 days following initial OKT3 exposure. Identical aliquots of all 270 sera were tested for IgG anti-OKT3 antibody by each laboratory. In addition, the limit of detection of each laboratory's method was estimated by titration of an affinity-purified IgG anti-OKT3 reference material of known concentration. Anti-OKT3 antibody formation differed greatly among the three organ groups. Cardiac patients demonstrated the least sensitization and almost exclusively lower titres, while kidney recipients had more frequent and higher titre antibody formation. Liver recipients yielded the highest sensitization rate and the most frequent high titre sera. Importantly, the seven laboratories differed widely in the number of pretreatment sera reported as positive (ranging from 0{\%} to 41{\%} among laboratories), the number of post-OKT3 sera reported as positive (17-63{\%}), the number of post-OKT3 samples with titre ≥1000 (2-31{\%}), and the number of agreement ranging from 38{\%} to 83{\%} on the sample titres assigned to 180 post-OKT3 sera. Many of the discordant results were consistent with differences in the limit of detection of the analytical methods, which ranged from 0.19 μg/ml to ≥15 μg/ml, a nearly 100-fold difference among laboratories. This study demonstrated the presence of both good concordance and significant discordance among laboratories in determining human anti-mouse antibody titres, and demonstrated that common titre categories (100, 1000, 10 000) were not equivalent among laboratories. The level of concordance among methods should be considered when comparing anti-OKT3 antibody results from different centres and their correlation with clinical events. Universal comparative testing, patterned after proficiency testing programmes, is needed to assess differences among laboratories and to bring uniformity and a sound interpretative basis to this field of testing.",
author = "Kimball, {JA A.} and Douglas Norman and Shield, {CF F.} and Schroeder, {TJ J.} and P. Lisi and M. Garovoy and O'Connell, {JB B.} and F. Stuart and McDiarmid, {SV V.} and W. Wall",
year = "1995",
doi = "10.1016/0966-3274(95)80027-1",
language = "English (US)",
volume = "3",
pages = "212--221",
journal = "Transplant Immunology",
issn = "0966-3274",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The OKT3 antibody response study

T2 - a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ tranplantation

AU - Kimball, JA A.

AU - Norman, Douglas

AU - Shield, CF F.

AU - Schroeder, TJ J.

AU - Lisi, P.

AU - Garovoy, M.

AU - O'Connell, JB B.

AU - Stuart, F.

AU - McDiarmid, SV V.

AU - Wall, W.

PY - 1995

Y1 - 1995

N2 - Human anti-murine antibody titres following patient exposure to the monoclonal antibody Orthoclone OKT®3 (muromonab-CD3) are determined by laboratories using diverse analytical methods which are not standardized and whose concordance is not established. A multicentre study group therefore compared testing for IgG anti-OKT3 antibody among seven laboratories. A set of 270 sera was obtained from 30 heart, 30 kidney and 30 liver transplant recipients with no previous exposure to OKT3 who were receiving OKT3 for induction immunosuppression. Sera were collected from each patient prior to and at 24 ± 2 days and 31 ± 2 days following initial OKT3 exposure. Identical aliquots of all 270 sera were tested for IgG anti-OKT3 antibody by each laboratory. In addition, the limit of detection of each laboratory's method was estimated by titration of an affinity-purified IgG anti-OKT3 reference material of known concentration. Anti-OKT3 antibody formation differed greatly among the three organ groups. Cardiac patients demonstrated the least sensitization and almost exclusively lower titres, while kidney recipients had more frequent and higher titre antibody formation. Liver recipients yielded the highest sensitization rate and the most frequent high titre sera. Importantly, the seven laboratories differed widely in the number of pretreatment sera reported as positive (ranging from 0% to 41% among laboratories), the number of post-OKT3 sera reported as positive (17-63%), the number of post-OKT3 samples with titre ≥1000 (2-31%), and the number of agreement ranging from 38% to 83% on the sample titres assigned to 180 post-OKT3 sera. Many of the discordant results were consistent with differences in the limit of detection of the analytical methods, which ranged from 0.19 μg/ml to ≥15 μg/ml, a nearly 100-fold difference among laboratories. This study demonstrated the presence of both good concordance and significant discordance among laboratories in determining human anti-mouse antibody titres, and demonstrated that common titre categories (100, 1000, 10 000) were not equivalent among laboratories. The level of concordance among methods should be considered when comparing anti-OKT3 antibody results from different centres and their correlation with clinical events. Universal comparative testing, patterned after proficiency testing programmes, is needed to assess differences among laboratories and to bring uniformity and a sound interpretative basis to this field of testing.

AB - Human anti-murine antibody titres following patient exposure to the monoclonal antibody Orthoclone OKT®3 (muromonab-CD3) are determined by laboratories using diverse analytical methods which are not standardized and whose concordance is not established. A multicentre study group therefore compared testing for IgG anti-OKT3 antibody among seven laboratories. A set of 270 sera was obtained from 30 heart, 30 kidney and 30 liver transplant recipients with no previous exposure to OKT3 who were receiving OKT3 for induction immunosuppression. Sera were collected from each patient prior to and at 24 ± 2 days and 31 ± 2 days following initial OKT3 exposure. Identical aliquots of all 270 sera were tested for IgG anti-OKT3 antibody by each laboratory. In addition, the limit of detection of each laboratory's method was estimated by titration of an affinity-purified IgG anti-OKT3 reference material of known concentration. Anti-OKT3 antibody formation differed greatly among the three organ groups. Cardiac patients demonstrated the least sensitization and almost exclusively lower titres, while kidney recipients had more frequent and higher titre antibody formation. Liver recipients yielded the highest sensitization rate and the most frequent high titre sera. Importantly, the seven laboratories differed widely in the number of pretreatment sera reported as positive (ranging from 0% to 41% among laboratories), the number of post-OKT3 sera reported as positive (17-63%), the number of post-OKT3 samples with titre ≥1000 (2-31%), and the number of agreement ranging from 38% to 83% on the sample titres assigned to 180 post-OKT3 sera. Many of the discordant results were consistent with differences in the limit of detection of the analytical methods, which ranged from 0.19 μg/ml to ≥15 μg/ml, a nearly 100-fold difference among laboratories. This study demonstrated the presence of both good concordance and significant discordance among laboratories in determining human anti-mouse antibody titres, and demonstrated that common titre categories (100, 1000, 10 000) were not equivalent among laboratories. The level of concordance among methods should be considered when comparing anti-OKT3 antibody results from different centres and their correlation with clinical events. Universal comparative testing, patterned after proficiency testing programmes, is needed to assess differences among laboratories and to bring uniformity and a sound interpretative basis to this field of testing.

UR - http://www.scopus.com/inward/record.url?scp=0028862395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028862395&partnerID=8YFLogxK

U2 - 10.1016/0966-3274(95)80027-1

DO - 10.1016/0966-3274(95)80027-1

M3 - Article

C2 - 8581409

AN - SCOPUS:0028862395

VL - 3

SP - 212

EP - 221

JO - Transplant Immunology

JF - Transplant Immunology

SN - 0966-3274

IS - 3

ER -